BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) gapped down before the market opened on Tuesday after HC Wainwright lowered their price target on the stock from $85.00 to $73.00. The stock had previously closed at $21.48, but opened at $21.00. HC Wainwright currently has a buy rating on the stock. BioXcel Therapeutics shares last traded at $20.98, with a volume of 206 shares.
A number of other equities research analysts also recently commented on the stock. Mizuho raised their price objective on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research report on Thursday, December 15th. Guggenheim reduced their price objective on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 11th. The Goldman Sachs Group upgraded shares of BioXcel Therapeutics from a “sell” rating to a “neutral” rating and set a $16.00 price objective for the company in a research report on Thursday, December 1st. Canaccord Genuity Group raised their price objective on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, November 11th. Finally, Canaccord Genuity Group lifted their price target on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, November 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.78.
Insider Transactions at BioXcel Therapeutics
In other news, CEO Vimal Mehta sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $19.44, for a total transaction of $583,200.00. Following the completion of the transaction, the chief executive officer now directly owns 9,957 shares of the company’s stock, valued at approximately $193,564.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other BioXcel Therapeutics news, Director Krishnan Nandabalan sold 27,450 shares of BioXcel Therapeutics stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $15.00, for a total value of $411,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vimal Mehta sold 30,000 shares of BioXcel Therapeutics stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the completion of the sale, the chief executive officer now directly owns 9,957 shares of the company’s stock, valued at $193,564.08. The disclosure for this sale can be found here. Corporate insiders own 37.00% of the company’s stock.
Institutional Trading of BioXcel Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of BTAI. Apis Capital Advisors LLC purchased a new stake in shares of BioXcel Therapeutics during the 1st quarter valued at $836,000. Walleye Capital LLC purchased a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $487,000. SG Americas Securities LLC purchased a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $574,000. PVG Asset Management Corp purchased a new stake in shares of BioXcel Therapeutics during the 3rd quarter valued at $178,000. Finally, Game Plan Financial Advisors LLC purchased a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $142,000. 42.35% of the stock is owned by hedge funds and other institutional investors.
BioXcel Therapeutics Price Performance
The company’s 50 day moving average price is $16.67 and its 200-day moving average price is $14.69. The company has a market capitalization of $588.98 million, a PE ratio of -4.39 and a beta of 1.16. The company has a current ratio of 10.34, a quick ratio of 10.28 and a debt-to-equity ratio of 0.72.
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.15). The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.05 million. On average, sell-side analysts forecast that BioXcel Therapeutics, Inc. will post -5.31 earnings per share for the current fiscal year.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.